What's New in SCLC? A Review

A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of th...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Neoplasia (New York, N.Y.) Ročník 19; číslo 10; s. 842 - 847
Hlavní autoři:	Oronsky, Bryan, Reid, Tony R., Oronsky, Arnold, Carter, Corey A.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.10.2017 Elsevier Limited Neoplasia Press Elsevier
Témata:	Clinical trials DNA-directed RNA polymerase Drug development Epidemiology Epidermal growth factor receptors Humans Immune checkpoint Immunotherapy Lung Neoplasms - diagnosis Lung Neoplasms - epidemiology Lung Neoplasms - etiology Lung Neoplasms - therapy Molecular Targeted Therapy Neoplasm Staging Non-small cell lung carcinoma Poly(ADP-ribose) polymerase Prevalence Prognosis Review article Reviews RNA polymerase Small cell lung carcinoma Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - epidemiology Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - therapy TOR protein Treatment Outcome Vascular endothelial growth factor
ISSN:	1476-5586, 1522-8002, 1476-5586, 1522-8002
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of them, in fact, including inhibitors of VEGF, IGFR, mTOR, EGFR and HGF has failed and fallen by the wayside due to little or no impact on PFS or OS, while SCLC's cousin, NSCLC, has notched success after success with a spate of targeted treatment and immunotherapy regulatory approvals. However, a paradigm shift or, more appropriately, a ‘paradigm nudge’ is quietly underway in extensive stage SCLC with a series of agents that in early clinical trials have shown the potential to ‘lift the curse’ in SCLC, heretofore referred to as “a graveyard for drug development”. These agents, constituting the “best of what's new” in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate immune activator, and an inhibitor of RNA polymerase II. Compared to NSCLC, the therapeutic options are still limited but with one or more successes to build momentum and drive long-overdue R&D and clinical investment the hope is that the approval floodgates may finally open.
AbstractList	A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of them, in fact, including inhibitors of VEGF, IGFR, mTOR, EGFR and HGF has failed and fallen by the wayside due to little or no impact on PFS or OS, while SCLC's cousin, NSCLC, has notched success after success with a spate of targeted treatment and immunotherapy regulatory approvals. However, a paradigm shift or, more appropriately, a ‘paradigm nudge’ is quietly underway in extensive stage SCLC with a series of agents that in early clinical trials have shown the potential to ‘lift the curse’ in SCLC, heretofore referred to as “a graveyard for drug development”. These agents, constituting the “best of what's new” in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate immune activator, and an inhibitor of RNA polymerase II. Compared to NSCLC, the therapeutic options are still limited but with one or more successes to build momentum and drive long-overdue R&D and clinical investment the hope is that the approval floodgates may finally open. A few years ago the answer to the question in the title of this review would have been, "unfortunately not much" or even "nothing", likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of them, in fact, including inhibitors of VEGF, IGFR, mTOR, EGFR and HGF has failed and fallen by the wayside due to little or no impact on PFS or OS, while SCLC's cousin, NSCLC, has notched success after success with a spate of targeted treatment and immunotherapy regulatory approvals. However, a paradigm shift or, more appropriately, a 'paradigm nudge' is quietly underway in extensive stage SCLC with a series of agents that in early clinical trials have shown the potential to 'lift the curse' in SCLC, heretofore referred to as "a graveyard for drug development". These agents, constituting the "best of what's new" in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate immune activator, and an inhibitor of RNA polymerase II. Compared to NSCLC, the therapeutic options are still limited but with one or more successes to build momentum and drive long-overdue R&D and clinical investment the hope is that the approval floodgates may finally open.A few years ago the answer to the question in the title of this review would have been, "unfortunately not much" or even "nothing", likely eliciting knowing nods of agreement from oncologists. For the last 3 decades, SCLC has been notorious for its lack of progress, as drug after drug, over 60 of them, in fact, including inhibitors of VEGF, IGFR, mTOR, EGFR and HGF has failed and fallen by the wayside due to little or no impact on PFS or OS, while SCLC's cousin, NSCLC, has notched success after success with a spate of targeted treatment and immunotherapy regulatory approvals. However, a paradigm shift or, more appropriately, a 'paradigm nudge' is quietly underway in extensive stage SCLC with a series of agents that in early clinical trials have shown the potential to 'lift the curse' in SCLC, heretofore referred to as "a graveyard for drug development". These agents, constituting the "best of what's new" in SCLC, and discussed in this review following a brief overview of the classification, epidemiology, prognosis and current treatment of SCLC, include checkpoint inhibitors, antibody-drug conjugates, PARP inhibitors, epigenetic inhibitor/innate immune activator, and an inhibitor of RNA polymerase II. Compared to NSCLC, the therapeutic options are still limited but with one or more successes to build momentum and drive long-overdue R&D and clinical investment the hope is that the approval floodgates may finally open.
Author	Oronsky, Arnold Oronsky, Bryan Reid, Tony R. Carter, Corey A.
AuthorAffiliation	InterWest Partners, 2710 Sand Hill Road #200, Menlo Park, CA 94025, USA Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA EpicentRx Inc, 4445 Eastgate Mall, Suite 200, San Diego, CA 92121, USA University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA 92093, USA
AuthorAffiliation_xml	– name: University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA 92093, USA – name: Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA – name: EpicentRx Inc, 4445 Eastgate Mall, Suite 200, San Diego, CA 92121, USA – name: InterWest Partners, 2710 Sand Hill Road #200, Menlo Park, CA 94025, USA
Author_xml	– sequence: 1 givenname: Bryan surname: Oronsky fullname: Oronsky, Bryan email: boronsky@epicentrx.com organization: EpicentRx Inc, 4445 Eastgate Mall, Suite 200, San Diego, CA 92121, USA – sequence: 2 givenname: Tony R. surname: Reid fullname: Reid, Tony R. organization: University of California San Diego, Moores Cancer Center, 3855 Health Sciences Dr, La Jolla, CA 92093, USA – sequence: 3 givenname: Arnold surname: Oronsky fullname: Oronsky, Arnold organization: InterWest Partners, 2710 Sand Hill Road #200, Menlo Park, CA 94025, USA – sequence: 4 givenname: Corey A. surname: Carter fullname: Carter, Corey A. organization: Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD 20889, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28888101$$D View this record in MEDLINE/PubMed
BookMark	eNqFkV9rFDEUxYNU7B_9AILIgA_6smuySSYTBKUsagtLC1XxMWTu3Gkzzk5qMtvSb-9dt5Z2H2oIJCTn_G5yzz7bGeKAjL0UfCq4KN930wHjdMaFmXKa3Dxhe0KZcqJ1Ve7c2--y_Zw7Th5hzDO2O6toEGKPvfp54ce3uTjB6yIMxbf5Yv6pOCzO8Crg9XP2tPV9xhe36wH78eXz9_nRZHH69Xh-uJiAtnqcVDPZlrbhrVLW1MJoU7ceLWihtBdacFAgWoUzNJVsUDXAuaysrHmjDDSNPGDHG24TfecuU1j6dOOiD-7vQUznzqcxQI8OLJey8lBLU9LvWquq2hLZgpSKShHr44Z1uaqX2AAOY_L9A-jDmyFcuPN45bS2pdQlAd7dAlL8vcI8umXIgH3vqdmr7ISVRktRGUPSN1vSLq7SQK0ildVClkZpUr2-_6K7p_wLgQRiI4AUc07Y3kkEd-ugXeeotlsH7ThNvi5ttjwQRj-GuP5U6B91ftg4kRKllJPLEHAAbEJCGKnl4VG33XJDH4YAvv-FN__x_gGoqtET
CitedBy_id	crossref_primary_10_3389_fpubh_2025_1552734 crossref_primary_10_3390_cells12151980 crossref_primary_10_1016_j_canlet_2022_215719 crossref_primary_10_1016_j_talanta_2022_124048 crossref_primary_10_1080_17512433_2021_1911640 crossref_primary_10_3389_fonc_2020_602185 crossref_primary_10_1080_07853890_2025_2542434 crossref_primary_10_3389_fmed_2019_00336 crossref_primary_10_1080_0284186X_2019_1711165 crossref_primary_10_3389_fimmu_2025_1556100 crossref_primary_10_1097_COC_0000000000000657 crossref_primary_10_1016_j_rmcr_2020_101074 crossref_primary_10_1186_s13023_024_03240_8 crossref_primary_10_1038_s41598_019_48476_8 crossref_primary_10_1177_1534735419890020 crossref_primary_10_3389_fphar_2022_967559 crossref_primary_10_3389_fphar_2022_1019826 crossref_primary_10_1002_cam4_4736 crossref_primary_10_3389_fonc_2024_1485849 crossref_primary_10_1007_s12033_021_00443_3 crossref_primary_10_1177_1758835920977137 crossref_primary_10_1007_s10637_021_01183_6 crossref_primary_10_1016_S1470_2045_20_30539_8 crossref_primary_10_1016_j_cllc_2019_12_006 crossref_primary_10_1016_j_lungcan_2024_108079 crossref_primary_10_1016_j_radonc_2024_110619 crossref_primary_10_1007_s12325_021_01675_0 crossref_primary_10_1111_cas_14196 crossref_primary_10_1016_j_jtocrr_2020_100109 crossref_primary_10_1016_j_snb_2025_137353 crossref_primary_10_3389_fmolb_2025_1506768 crossref_primary_10_1080_14737167_2023_2281606 crossref_primary_10_3892_ol_2019_11193 crossref_primary_10_1186_s12913_023_09727_7 crossref_primary_10_1080_1061186X_2021_1987442 crossref_primary_10_1007_s00259_022_06059_2 crossref_primary_10_1016_S0140_6736_19_32235_4 crossref_primary_10_1038_s41429_019_0258_9 crossref_primary_10_1136_bmjopen_2023_072106 crossref_primary_10_1177_1073274820932004 crossref_primary_10_1016_j_lungcan_2021_07_007 crossref_primary_10_1016_j_jtho_2019_11_031 crossref_primary_10_1001_jamanetworkopen_2020_15748 crossref_primary_10_1007_s11523_021_00843_0 crossref_primary_10_3389_fmolb_2022_913043 crossref_primary_10_1111_1759_7714_14729 crossref_primary_10_1186_s12885_023_10797_3 crossref_primary_10_3389_fimmu_2024_1327449 crossref_primary_10_1007_s00408_022_00536_z crossref_primary_10_1016_j_intimp_2019_106088 crossref_primary_10_3892_ol_2025_15073 crossref_primary_10_3389_fonc_2021_740091 crossref_primary_10_1080_14728222_2020_1732353 crossref_primary_10_1002_rcr2_741 crossref_primary_10_3389_fonc_2021_699781 crossref_primary_10_3389_fmed_2022_834725 crossref_primary_10_3390_ijms23136895 crossref_primary_10_1007_s10616_025_00807_6 crossref_primary_10_1093_annonc_mdy326 crossref_primary_10_1111_crj_13242 crossref_primary_10_1136_bmjopen_2023_077090 crossref_primary_10_1177_10732748241274195 crossref_primary_10_2217_fon_2022_1315 crossref_primary_10_1136_jitc_2023_007987 crossref_primary_10_1177_10732748251347679 crossref_primary_10_1177_10732748211028257 crossref_primary_10_3892_or_2022_8333 crossref_primary_10_1007_s13402_019_00441_3 crossref_primary_10_1038_s41598_023_42725_7 crossref_primary_10_3389_fonc_2020_01146 crossref_primary_10_1111_1759_7714_14697 crossref_primary_10_1080_13543784_2021_1863947 crossref_primary_10_1080_17425247_2020_1761787 crossref_primary_10_1097_MD_0000000000027029 crossref_primary_10_1097_MD_0000000000035962 crossref_primary_10_1186_s12935_025_03785_z crossref_primary_10_1007_s10585_023_10227_5 crossref_primary_10_1038_s41420_023_01591_y crossref_primary_10_1002_msp2_46 crossref_primary_10_3390_cancers16193291 crossref_primary_10_1158_1078_0432_CCR_21_1533 crossref_primary_10_1016_j_canlet_2020_11_034 crossref_primary_10_1016_j_lungcan_2018_03_026 crossref_primary_10_1016_j_clon_2024_06_056 crossref_primary_10_3390_jcm12113828 crossref_primary_10_3389_fonc_2024_1391828 crossref_primary_10_1002_cai2_155 crossref_primary_10_1007_s00432_021_03798_x crossref_primary_10_3892_ol_2025_15264 crossref_primary_10_1007_s13691_023_00640_8 crossref_primary_10_1097_CAD_0000000000000969 crossref_primary_10_1002_onco_13954 crossref_primary_10_1371_journal_pone_0230979 crossref_primary_10_2147_IJGM_S457329 crossref_primary_10_1111_crj_13715 crossref_primary_10_1186_s40001_023_01044_3 crossref_primary_10_1186_s12935_020_1157_7 crossref_primary_10_1186_s12864_023_09306_4 crossref_primary_10_1007_s10555_024_10207_5 crossref_primary_10_3390_cancers14112689 crossref_primary_10_1016_j_imu_2021_100676 crossref_primary_10_1158_1078_0432_CCR_20_2150 crossref_primary_10_1080_1061186X_2020_1797050 crossref_primary_10_1007_s12325_021_01909_1 crossref_primary_10_1002_jcb_28809 crossref_primary_10_1002_mco2_760 crossref_primary_10_1111_1759_7714_13432 crossref_primary_10_1007_s00262_021_03017_z crossref_primary_10_1016_S0140_6736_19_32222_6 crossref_primary_10_2217_fon_2021_1027 crossref_primary_10_1186_s40792_023_01759_9 crossref_primary_10_1007_s00432_021_03858_2 crossref_primary_10_1186_s12880_021_00602_7 crossref_primary_10_1016_j_jtocrr_2022_100330 crossref_primary_10_1016_j_lungcan_2020_09_003 crossref_primary_10_1155_2022_3645489 crossref_primary_10_1002_cam4_5360 crossref_primary_10_1080_14737167_2021_1888717 crossref_primary_10_3389_fphar_2025_1539246 crossref_primary_10_3389_fcell_2019_00221 crossref_primary_10_1186_s13014_024_02420_x crossref_primary_10_1111_1759_7714_15225 crossref_primary_10_1016_j_omton_2024_200875
Cites_doi	10.1172/JCI81603 10.1016/j.ccm.2011.09.001 10.3816/CLC.2008.n.041 10.1007/s00432-017-2416-4 10.1097/JTO.0b013e31815bdc0d 10.1016/S1470-2045(14)71180-5 10.1200/JCO.1999.17.6.1794 10.1200/JCO.1999.17.2.658 10.1200/JCO.2011.41.5166 10.1200/jco.2015.33.15_suppl.7502 10.3332/ecancer.2017.729 10.1158/1538-7445.AM2017-CT155 10.1158/1535-7163.MCT-11-0252 10.1080/13543784.2017.1268600 10.1200/JCO.2016.34.15_suppl.8559 10.1097/00001813-200504000-00002 10.1016/j.pharmthera.2017.06.002 10.1016/j.cllc.2013.11.003 10.1016/j.jtho.2016.11.466 10.1002/14651858.CD001990.pub2 10.1016/S1535-6108(03)00220-4 10.1016/j.hoc.2003.12.010 10.1002/cncr.24858 10.1200/jco.2006.24.18_suppl.7082 10.1093/jnci/djw119 10.3390/ijms17071151 10.1242/dmm.026369 10.1200/JCO.2005.04.4859 10.3322/caac.20107 10.2217/lmt.15.14 10.1016/j.cllc.2016.06.006 10.1200/JCO.2016.67.6601
ContentType	Journal Article
Copyright	2017 The Authors Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. Copyright Neoplasia Press Oct 2017 2017 The Authors 2017
Copyright_xml	– notice: 2017 The Authors – notice: Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. – notice: Copyright Neoplasia Press Oct 2017 – notice: 2017 The Authors 2017
DBID	6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TK 7TO 8FD FR3 H94 P64 RC3 7X8 5PM DOA
DOI	10.1016/j.neo.2017.07.007
DatabaseName	ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Genetics Abstracts MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1476-5586 1522-8002
EndPage	847
ExternalDocumentID	oai_doaj_org_article_c90338acb376476f948b9e2e9c334510 PMC5596356 28888101 10_1016_j_neo_2017_07_007 S1476558617302701
Genre	Journal Article Review
GroupedDBID	--- .1- .FO 0R~ 123 1P~ 29M 2WC 36B 4.4 457 53G AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO ABDBF ABFRF ABMAC ACGFO ACGFS ACPRK ACUHS ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AENEX AEUPX AEVXI AEXQZ AFJKZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV CAG COF CS3 DIK DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX F5P FDB GROUPED_DOAJ GX1 HYE IPNFZ IXB KQ8 OC~ OK1 OO- OVT P2P RIG RNS ROL RPM SSZ SV3 UNMZH W2D WOQ Z5R 0SF 6I. AACTN AAFTH AFCTW M~E NCXOZ AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TK 7TO 8FD FR3 H94 P64 RC3 7X8 5PM
ID	FETCH-LOGICAL-c595t-823f69d0f4497b1757bfae9c5145a1510c4c1f4e2e783de4dc003893b0d47cdd3
IEDL.DBID	DOA
ISICitedReferencesCount	159
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000411874100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1476-5586 1522-8002
IngestDate	Fri Oct 03 12:45:00 EDT 2025 Thu Aug 21 18:16:59 EDT 2025 Wed Oct 01 13:50:24 EDT 2025 Sat Nov 15 13:22:57 EST 2025 Mon Jul 21 05:49:20 EDT 2025 Sat Nov 29 02:38:51 EST 2025 Tue Nov 18 22:33:07 EST 2025 Fri Feb 23 02:28:59 EST 2024 Tue Aug 26 17:10:12 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Language	English
License	This is an open access article under the CC BY-NC-ND license. Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c595t-823f69d0f4497b1757bfae9c5145a1510c4c1f4e2e783de4dc003893b0d47cdd3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
OpenAccessLink	https://doaj.org/article/c90338acb376476f948b9e2e9c334510
PMID	28888101
PQID	1995136745
PQPubID	2047877
PageCount	6
ParticipantIDs	doaj_primary_oai_doaj_org_article_c90338acb376476f948b9e2e9c334510 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5596356 proquest_miscellaneous_1937531877 proquest_journals_1995136745 pubmed_primary_28888101 crossref_primary_10_1016_j_neo_2017_07_007 crossref_citationtrail_10_1016_j_neo_2017_07_007 elsevier_sciencedirect_doi_10_1016_j_neo_2017_07_007 elsevier_clinicalkey_doi_10_1016_j_neo_2017_07_007
PublicationCentury	2000
PublicationDate	2017-10-01
PublicationDateYYYYMMDD	2017-10-01
PublicationDate_xml	– month: 10 year: 2017 text: 2017-10-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Oxford
PublicationTitle	Neoplasia (New York, N.Y.)
PublicationTitleAlternate	Neoplasia
PublicationYear	2017
Publisher	Elsevier Inc Elsevier Limited Neoplasia Press Elsevier
Publisher_xml	– name: Elsevier Inc – name: Elsevier Limited – name: Neoplasia Press – name: Elsevier
References	Oser, Niederst, Sequist, Engelman (bb0055) 2015; 16 Dela Cruz, Tanoue, Matthat (bb0060) 2011; 32 Wagar, Morgensztern (bb0115) 2017 Forster, Calvo, Olmedo Garcia, Lopez Criado, Moreno, Soto-Matos, Holgado, Brown, Flynn, Boni (bb0175) 2015 Oronsky, Scicinski, Ning, Peehl, Oronsky, Cabrales, Bednarski, Knox (bb0180) 2016; 21 Pietanza (bb0145) 2015 Casciato, Territo (bb0050) 2009 Soares, Machado, Rocca, Poindessous, Ouaret, Sarasin, Galmarini, Henriques, Escargueil, Larsen (bb0165) 2010; 10 Meuwissen, Linn, Linnoila, Zevenhoven, Mooi, Berns (bb0025) 2003; 4 Pelayo, Gallego, Bonfill, Agra (bb0080) 2009 Oronsky, Paulmurugan, Foygel, Scicinski, Knox, Peehl, Zhao, Ning, Cabrales, Summers (bb0185) 2017; 26 Hellmann, Antonia, Ponce, Ott, Calvo, Taylor, Ready, Hann, De Braud, Eder (bb0130) 2016 Mamdani, Induru, Jalal (bb0010) 2015; 4 Chan, Coward (bb0110) 2013; 5 Von Pawel, Schiller, Shepherd, Fields, Kleisbauer, Chrysson, Stewart, Clark, Palmer, Depierre (bb0100) 1999; 17 Ott, Elez Fernandez, Hiret, Kim, Moss, Winser, Yuan, Cheng, Piperdi, Mehnert (bb0125) 2015; 33 Jemal, Bray, Center, Ferlay, Ward, Forman (bb0040) 2011; 61 Li, Li, Jiang, Lv, Zhang, Lu, Zhang (bb0140) 2016; 17 Chute, Chen, Feigal, Simon, Johnson (bb0200) 1999; 17 Allen, Jahanzeb (bb0075) 2008; 9 Bassiri, Cairns, McVie, Seckl (bb0210) 2017; 11 Céspedes, Guillén, López-Casas, Sarno, Gallardo, Alamo, Cuevas, Hidalgo, Galmarini, Allavena (bb0170) 2016; 9 Simos, Sajjady, Sergi, Liew, Califano, Ho, Leighl, White, Summers, Petrcich (bb0090) 2014; 15 Gray JE, Heist RS, Starodub AN, Camidge DS, Kio E, Masters G, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, et al. CT155-Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC). [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT155. Altekruse, Kosary, Krapcho, Neyman, Aminou, Waldron, Ruhl, Howlader, Tatalovich, Cho (bb0020) 2010 Oronsky, Reid, Larson, Carter, Brzezniak, Oronsky, Cabrales (bb0195) 2017 Popat, O'Brien (bb0205) 2005; 16 Govindan, Page, Morgensztern, Read, Tierney, Vlahiotis, Spitznagel, Piccirillo (bb0015) 2006; 24 Shepherd, Crowley, Van Houtte, Postmus, Carney, Chansky, Shaikh, Goldstraw (bb0095) 2007; 2 Khanna, Blais, Gaudreau, Corrales-Rodriguez (bb0005) 2017; 18 . Weiskopf, Jahchan, Schnorr, Cristea, Ring, Maute, Volkmer, Volkmer, Liu, Lim (bb0190) 2016; 126 Brennan, Gregory, Stillie, Herschtal, Mac Manus, Ball (bb0065) 2010; 116 Starodub, Camidge, Ronald, Scheff, Thomas, Guarino, Masters, Kalinsky, Gandhi, Bardia (bb0150) 2016; 34 Navada, Lai, Schwartz, Kalemkerian (bb0030) 2006; 24 Gazdar, Minna (bb0105) 2016; 108 Pokharel, Gilbar, Sorour (bb0045) 2015; 4 Davies, Evans, Mackay, Shepherd (bb0085) 2004; 18 Reck, Luft, Szczesna, Havel, Kim, Akerley, Pietanza, Wu, Zielinski, Thomas (bb0135) 2016; 25 (bb0035) 2015 Beltran, Tagawa, Park, MacDonald, Milowsky, Mosquera, Rubin, Nanus (bb0070) 2012; 30 Mattern, Mong, Bartus, Mirabelli, Crooke, Johnson (bb0120) 1987; 47 Byers, Krug, Waqar, Dowlati, Hann, Chiappori, Owonikoko, Woo, Bensman, Hurtado (bb0160) 2017; 12 Govindan (10.1016/j.neo.2017.07.007_bb0015) 2006; 24 Céspedes (10.1016/j.neo.2017.07.007_bb0170) 2016; 9 Oronsky (10.1016/j.neo.2017.07.007_bb0195) 2017 Jemal (10.1016/j.neo.2017.07.007_bb0040) 2011; 61 Chan (10.1016/j.neo.2017.07.007_bb0110) 2013; 5 (10.1016/j.neo.2017.07.007_bb0035) 2015 Gazdar (10.1016/j.neo.2017.07.007_bb0105) 2016; 108 Meuwissen (10.1016/j.neo.2017.07.007_bb0025) 2003; 4 Davies (10.1016/j.neo.2017.07.007_bb0085) 2004; 18 Pelayo (10.1016/j.neo.2017.07.007_bb0080) 2009 Bassiri (10.1016/j.neo.2017.07.007_bb0210) 2017; 11 Byers (10.1016/j.neo.2017.07.007_bb0160) 2017; 12 Shepherd (10.1016/j.neo.2017.07.007_bb0095) 2007; 2 Mamdani (10.1016/j.neo.2017.07.007_bb0010) 2015; 4 Allen (10.1016/j.neo.2017.07.007_bb0075) 2008; 9 Oronsky (10.1016/j.neo.2017.07.007_bb0185) 2017; 26 Beltran (10.1016/j.neo.2017.07.007_bb0070) 2012; 30 Dela Cruz (10.1016/j.neo.2017.07.007_bb0060) 2011; 32 Starodub (10.1016/j.neo.2017.07.007_bb0150) 2016; 34 Popat (10.1016/j.neo.2017.07.007_bb0205) 2005; 16 Mattern (10.1016/j.neo.2017.07.007_bb0120) 1987; 47 Chute (10.1016/j.neo.2017.07.007_bb0200) 1999; 17 Khanna (10.1016/j.neo.2017.07.007_bb0005) 2017; 18 10.1016/j.neo.2017.07.007_bb0155 Oronsky (10.1016/j.neo.2017.07.007_bb0180) 2016; 21 Hellmann (10.1016/j.neo.2017.07.007_bb0130) 2016 Pokharel (10.1016/j.neo.2017.07.007_bb0045) 2015; 4 Von Pawel (10.1016/j.neo.2017.07.007_bb0100) 1999; 17 Casciato (10.1016/j.neo.2017.07.007_bb0050) 2009 Weiskopf (10.1016/j.neo.2017.07.007_bb0190) 2016; 126 Ott (10.1016/j.neo.2017.07.007_bb0125) 2015; 33 Altekruse (10.1016/j.neo.2017.07.007_bb0020) 2010 Li (10.1016/j.neo.2017.07.007_bb0140) 2016; 17 Reck (10.1016/j.neo.2017.07.007_bb0135) 2016; 25 Simos (10.1016/j.neo.2017.07.007_bb0090) 2014; 15 Brennan (10.1016/j.neo.2017.07.007_bb0065) 2010; 116 Wagar (10.1016/j.neo.2017.07.007_bb0115) 2017 Navada (10.1016/j.neo.2017.07.007_bb0030) 2006; 24 Oser (10.1016/j.neo.2017.07.007_bb0055) 2015; 16 Pietanza (10.1016/j.neo.2017.07.007_bb0145) 2015 Forster (10.1016/j.neo.2017.07.007_bb0175) 2015 Soares (10.1016/j.neo.2017.07.007_bb0165) 2010; 10
References_xml	– volume: 61 start-page: 69 year: 2011 end-page: 90 ident: bb0040 article-title: Global cancer statistics publication-title: CA Cancer J Clin – volume: 17 start-page: 1794 year: 1999 end-page: 1801 ident: bb0200 article-title: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress publication-title: J Clin Oncol – volume: 11 start-page: 729 year: 2017 ident: bb0210 article-title: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC publication-title: Ecancermedicalscience – year: 2015 ident: bb0145 article-title: Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein3 (DLL3)-targeted anibody drug conjugate (ADC), in small cell lung cancer (SCLC) [abstract LBA 7] publication-title: Presented at the ECC 2015 – volume: 4 start-page: 181 year: 2003 end-page: 189 ident: bb0025 article-title: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model publication-title: Cancer Cell – year: 2015 ident: bb0035 publication-title: Small Cell Lung Cancer Treatment (PDQQR): Health Professional Version – year: 2017 ident: bb0195 article-title: RRx-001 protects against cisplatin-induced toxicities publication-title: J Cancer Res Clin Oncol – volume: 24 start-page: 7082-7082 year: 2006 ident: bb0030 article-title: Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End Results database (abstract 7082) publication-title: J Clin Oncol – year: 2009 ident: bb0080 article-title: Chemotherapy versus best supportive care for extensive small cell lung cancer publication-title: Cochrane Database Syst Rev – volume: 17 start-page: 658 year: 1999 end-page: 667 ident: bb0100 article-title: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer publication-title: J Clin Oncol – volume: 4 start-page: 533 year: 2015 end-page: 544 ident: bb0010 article-title: Novel therapies in small cell lung cancer publication-title: Transl Lung Cancer Res – volume: 34 start-page: 8559-8559 year: 2016 ident: bb0150 article-title: Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC) publication-title: J Clin Oncol – volume: 32 year: 2011 ident: bb0060 article-title: Lung Cancer: Epidemiology, Etiology, and Prevention publication-title: Clin Chest Med – volume: 18 start-page: 387 year: 2004 end-page: 416 ident: bb0085 article-title: Treatment of recurrent small cell lung cancer publication-title: Hematol Oncol Clin North Am – volume: 47 start-page: 1793 year: 1987 end-page: 1798 ident: bb0120 article-title: Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells publication-title: Cancer Res – reference: Gray JE, Heist RS, Starodub AN, Camidge DS, Kio E, Masters G, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, et al. CT155-Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC). [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT155. – volume: 16 start-page: 361 year: 2005 end-page: 372 ident: bb0205 article-title: Chemotherapy strategies in the treatment of small cell lung cancer publication-title: Anticancer Drugs – year: 2009 ident: bb0050 article-title: Manual of Clinical Oncology – volume: 116 start-page: 888 year: 2010 end-page: 895 ident: bb0065 article-title: Should extrapulmonary small cell cancer be managed like small cell lung cancer? publication-title: Cancer – year: 2016 ident: bb0130 article-title: Nivolumab alone or with ipilimumab in recurrent small cell lung cancer: 2-year survival and updated analyses from the CheckMate 032 trial publication-title: World Conference on Lung Cancer. Abstract MA09.05. Presented December 6, 2016 – volume: 10 start-page: 1481 year: 2010 end-page: 1489 ident: bb0165 article-title: Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells publication-title: Mol Cancer Ther – volume: 30 start-page: e386 year: 2012 end-page: 9 ident: bb0070 article-title: Challenges in recognizing treatment-related neuroendocrine prostate cancer publication-title: J Clin Oncol – volume: 12 start-page: S406 year: 2017 end-page: S407 ident: bb0160 article-title: MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial publication-title: J Thorac Oncol – volume: 4 start-page: 159 year: 2015 end-page: 162 ident: bb0045 article-title: Case Report: Small-cell lung cancer in a young, female, never-smoker publication-title: Lung Cancer Manage – volume: 26 start-page: 109 year: 2017 end-page: 119 ident: bb0185 article-title: Carter CA.RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials publication-title: Expert Opin Investig Drugs – volume: 9 start-page: 262 year: 2008 end-page: 270 ident: bb0075 article-title: Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions publication-title: Clin Lung Cancer – volume: 126 start-page: 2610 year: 2016 end-page: 2620 ident: bb0190 article-title: CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer publication-title: J Clin Invest – volume: 25 start-page: 3740 year: 2016 end-page: 3748 ident: bb0135 article-title: Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer publication-title: J Clin Oncol – volume: 108 year: 2016 ident: bb0105 article-title: Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer publication-title: J Natl Cancer Inst – year: 2015 ident: bb0175 article-title: Lurbinectedin(PM1183)with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC). Presented at: 2015 ASCO Annual Meeting; May 29–June 2, 2015 publication-title: Chicago, IL – volume: 5 start-page: S565 year: 2013 end-page: 78 ident: bb0110 article-title: Chemotherapy advances in small-cell lung cancer publication-title: J Thorac Dis – volume: 18 start-page: 13 year: 2017 end-page: 22 ident: bb0005 article-title: Immunotherapy Comes of Age in Lung Cancer publication-title: Clin Lung Cancer – volume: 2 start-page: 1067 year: 2007 end-page: 1077 ident: bb0095 article-title: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer publication-title: J Thorac Oncol – year: 2010 ident: bb0020 article-title: SEER Cancer Statistics Review, 1975–2007 – reference: . – volume: 33 start-page: 7502-7502 year: 2015 ident: bb0125 article-title: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028 publication-title: J Clin Oncol – volume: 24 start-page: 4539 year: 2006 end-page: 4544 ident: bb0015 article-title: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database publication-title: J Clin Oncol – volume: 16 start-page: e165 year: 2015 end-page: e172 ident: bb0055 article-title: Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin publication-title: Lancet Oncol – volume: 21 start-page: 173 year: 2016 end-page: 180 ident: bb0180 article-title: Rockets, radiosensitizers, and RRx-001:an origin story part I publication-title: Discov Med – volume: 17 year: 2016 ident: bb0140 article-title: A Mini-Review for Cancer Immunother- apy: Molecular Understanding of PD-1/PD-L1 Pathway & amp;amp; Translational Blockade of Immune Checkpoints publication-title: Int J Mol Sci – volume: 9 start-page: 1461 year: 2016 end-page: 1471 ident: bb0170 article-title: Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models publication-title: Dis Model Mech – year: 2017 ident: bb0115 article-title: Treatment advances in small cell lung cancer (SCLC) publication-title: Pharmacol Ther – volume: 15 start-page: 110 year: 2014 end-page: 118 ident: bb0090 article-title: Third-line chemotherapy in small-cell lung cancer: an international analysis publication-title: Clin Lung Cancer – volume: 126 start-page: 2610 issue: 7 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0190 article-title: CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer publication-title: J Clin Invest doi: 10.1172/JCI81603 – year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0130 article-title: Nivolumab alone or with ipilimumab in recurrent small cell lung cancer: 2-year survival and updated analyses from the CheckMate 032 trial – year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0035 – volume: 32 issue: 4 year: 2011 ident: 10.1016/j.neo.2017.07.007_bb0060 article-title: Lung Cancer: Epidemiology, Etiology, and Prevention publication-title: Clin Chest Med doi: 10.1016/j.ccm.2011.09.001 – volume: 9 start-page: 262 issue: 5 year: 2008 ident: 10.1016/j.neo.2017.07.007_bb0075 article-title: Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions publication-title: Clin Lung Cancer doi: 10.3816/CLC.2008.n.041 – year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0195 article-title: RRx-001 protects against cisplatin-induced toxicities publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-017-2416-4 – year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0145 article-title: Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein3 (DLL3)-targeted anibody drug conjugate (ADC), in small cell lung cancer (SCLC) [abstract LBA 7] publication-title: Presented at the ECC 2015 – volume: 2 start-page: 1067 issue: 12 year: 2007 ident: 10.1016/j.neo.2017.07.007_bb0095 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31815bdc0d – volume: 16 start-page: e165 issue: 4 year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0055 article-title: Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71180-5 – volume: 17 start-page: 1794 issue: 6 year: 1999 ident: 10.1016/j.neo.2017.07.007_bb0200 article-title: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.6.1794 – volume: 17 start-page: 658 year: 1999 ident: 10.1016/j.neo.2017.07.007_bb0100 article-title: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.2.658 – volume: 4 start-page: 533 issue: 5 year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0010 article-title: Novel therapies in small cell lung cancer publication-title: Transl Lung Cancer Res – volume: 30 start-page: e386 year: 2012 ident: 10.1016/j.neo.2017.07.007_bb0070 article-title: Challenges in recognizing treatment-related neuroendocrine prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2011.41.5166 – volume: 33 start-page: 7502-7502 issue: 15_suppl year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0125 article-title: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028 publication-title: J Clin Oncol doi: 10.1200/jco.2015.33.15_suppl.7502 – volume: 11 start-page: 729 year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0210 article-title: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC publication-title: Ecancermedicalscience doi: 10.3332/ecancer.2017.729 – ident: 10.1016/j.neo.2017.07.007_bb0155 doi: 10.1158/1538-7445.AM2017-CT155 – volume: 10 start-page: 1481 year: 2010 ident: 10.1016/j.neo.2017.07.007_bb0165 article-title: Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-11-0252 – volume: 26 start-page: 109 issue: 1 year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0185 article-title: Carter CA.RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2017.1268600 – volume: 34 start-page: 8559-8559 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0150 article-title: Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC) publication-title: J Clin Oncol doi: 10.1200/JCO.2016.34.15_suppl.8559 – volume: 16 start-page: 361 year: 2005 ident: 10.1016/j.neo.2017.07.007_bb0205 article-title: Chemotherapy strategies in the treatment of small cell lung cancer publication-title: Anticancer Drugs doi: 10.1097/00001813-200504000-00002 – year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0115 article-title: Treatment advances in small cell lung cancer (SCLC) publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2017.06.002 – volume: 15 start-page: 110 issue: 2 year: 2014 ident: 10.1016/j.neo.2017.07.007_bb0090 article-title: Third-line chemotherapy in small-cell lung cancer: an international analysis publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2013.11.003 – year: 2009 ident: 10.1016/j.neo.2017.07.007_bb0050 – volume: 12 start-page: S406 issue: 1 year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0160 article-title: MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2016.11.466 – volume: 47 start-page: 1793 year: 1987 ident: 10.1016/j.neo.2017.07.007_bb0120 article-title: Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells publication-title: Cancer Res – issue: 4 year: 2009 ident: 10.1016/j.neo.2017.07.007_bb0080 article-title: Chemotherapy versus best supportive care for extensive small cell lung cancer publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD001990.pub2 – volume: 4 start-page: 181 year: 2003 ident: 10.1016/j.neo.2017.07.007_bb0025 article-title: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model publication-title: Cancer Cell doi: 10.1016/S1535-6108(03)00220-4 – volume: 18 start-page: 387 issue: 2 year: 2004 ident: 10.1016/j.neo.2017.07.007_bb0085 article-title: Treatment of recurrent small cell lung cancer publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2003.12.010 – volume: 116 start-page: 888 issue: 4 year: 2010 ident: 10.1016/j.neo.2017.07.007_bb0065 article-title: Should extrapulmonary small cell cancer be managed like small cell lung cancer? publication-title: Cancer doi: 10.1002/cncr.24858 – volume: 24 start-page: 7082-7082 issue: 18_suppl year: 2006 ident: 10.1016/j.neo.2017.07.007_bb0030 article-title: Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End Results database (abstract 7082) publication-title: J Clin Oncol doi: 10.1200/jco.2006.24.18_suppl.7082 – volume: 108 issue: 10 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0105 article-title: Developing New, Rational Therapies for Recalcitrant Small Cell Lung Cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djw119 – volume: 21 start-page: 173 issue: 115 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0180 article-title: Rockets, radiosensitizers, and RRx-001:an origin story part I publication-title: Discov Med – volume: 5 start-page: S565 issue: Suppl. 5 year: 2013 ident: 10.1016/j.neo.2017.07.007_bb0110 article-title: Chemotherapy advances in small-cell lung cancer publication-title: J Thorac Dis – year: 2010 ident: 10.1016/j.neo.2017.07.007_bb0020 – volume: 17 issue: 7 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0140 article-title: A Mini-Review for Cancer Immunother- apy: Molecular Understanding of PD-1/PD-L1 Pathway & amp;amp; Translational Blockade of Immune Checkpoints publication-title: Int J Mol Sci doi: 10.3390/ijms17071151 – volume: 9 start-page: 1461 issue: 12 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0170 article-title: Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models publication-title: Dis Model Mech doi: 10.1242/dmm.026369 – volume: 24 start-page: 4539 issue: 28 year: 2006 ident: 10.1016/j.neo.2017.07.007_bb0015 article-title: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.4859 – volume: 61 start-page: 69 year: 2011 ident: 10.1016/j.neo.2017.07.007_bb0040 article-title: Global cancer statistics publication-title: CA Cancer J Clin doi: 10.3322/caac.20107 – volume: 4 start-page: 159 issue: 4 year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0045 article-title: Case Report: Small-cell lung cancer in a young, female, never-smoker publication-title: Lung Cancer Manage doi: 10.2217/lmt.15.14 – volume: 18 start-page: 13 issue: 1 year: 2017 ident: 10.1016/j.neo.2017.07.007_bb0005 article-title: Immunotherapy Comes of Age in Lung Cancer publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2016.06.006 – year: 2015 ident: 10.1016/j.neo.2017.07.007_bb0175 article-title: Lurbinectedin(PM1183)with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC). Presented at: 2015 ASCO Annual Meeting; May 29–June 2, 2015 publication-title: Chicago, IL – volume: 25 start-page: 3740 year: 2016 ident: 10.1016/j.neo.2017.07.007_bb0135 article-title: Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2016.67.6601
SSID	ssj0016177
Score	2.5874567
SecondaryResourceType	review_article
Snippet	A few years ago the answer to the question in the title of this review would have been, “unfortunately not much” or even “nothing”, likely eliciting knowing... A few years ago the answer to the question in the title of this review would have been, "unfortunately not much" or even "nothing", likely eliciting knowing...
SourceID	doaj pubmedcentral proquest pubmed crossref elsevier
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	842
SubjectTerms	Clinical trials DNA-directed RNA polymerase Drug development Epidemiology Epidermal growth factor receptors Humans Immune checkpoint Immunotherapy Lung Neoplasms - diagnosis Lung Neoplasms - epidemiology Lung Neoplasms - etiology Lung Neoplasms - therapy Molecular Targeted Therapy Neoplasm Staging Non-small cell lung carcinoma Poly(ADP-ribose) polymerase Prevalence Prognosis Review article Reviews RNA polymerase Small cell lung carcinoma Small Cell Lung Carcinoma - diagnosis Small Cell Lung Carcinoma - epidemiology Small Cell Lung Carcinoma - etiology Small Cell Lung Carcinoma - therapy TOR protein Treatment Outcome Vascular endothelial growth factor
Title	What's New in SCLC? A Review
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1476558617302701 https://dx.doi.org/10.1016/j.neo.2017.07.007 https://www.ncbi.nlm.nih.gov/pubmed/28888101 https://www.proquest.com/docview/1995136745 https://www.proquest.com/docview/1937531877 https://pubmed.ncbi.nlm.nih.gov/PMC5596356 https://doaj.org/article/c90338acb376476f948b9e2e9c334510
Volume	19
WOSCitedRecordID	wos000411874100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1476-5586 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0016177 issn: 1476-5586 databaseCode: DOA dateStart: 19990101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB50EfEivq2uUkEQhGIfSZOcRBcXD6sIKuwtNGmDK1JlH_5-J01bdhX0Yo_Ni3x5zAwz-QbglBijSK6jgMcKDRTGaKC0iQJlMpQfJiK5I0kasPt7PhyKh7lUXzYmzNEDO-AutAjRisq0wpNAWGoE4UoUcSF0khDqHleFTDTGVO0_QLlcpVXBFgGlPG38mVVkV1m9-otYxdpp88jOSaSKuH9BMP1UPL_HT84JpP4GrNeapH_lZrAJS0W5Bat3ta98G7qWlfts4uM15o9K_7E36F36V75zBuzAc__mqXcb1LkQAk0FnSKUiUlFHhpCBFMo8xmiiSCgvkMzlNqhJjoyBIFhPMkLhN_6_ESiwpwwnefJLnTK97LYBz-KjeYpRb0ERRNBc4gWRBWpEllscmaIB2GDh9Q1UbjNV_Emm4iwV4kQSguhDK37mnlw3jb5cCwZv1W-tiC3FS3BdfUDl13Wyy7_WnYP4maJZPOGFG897Gj028ikbVQrGE5x-KtZt9kDsj7hE2mftlu6O0I9OGmL8Wxah0uGPcxsnQStwYgz7GLPbZl21jHHD8fzgC1spgVYFkvK0UvF_41GoGUVPPgPHA9hzc7UhSd2oTMdz4ojWNGf09FkfAzLbMiPq6P1Bc2UII0
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=What%27s+New+in+SCLC%3F+A+Review&rft.jtitle=Neoplasia+%28New+York%2C+N.Y.%29&rft.au=Bryan+Oronsky&rft.au=Tony+R.+Reid&rft.au=Arnold+Oronsky&rft.au=Corey+A.+Carter&rft.date=2017-10-01&rft.pub=Elsevier&rft.issn=1476-5586&rft.eissn=1522-8002&rft.volume=19&rft.issue=10&rft.spage=842&rft.epage=847&rft_id=info:doi/10.1016%2Fj.neo.2017.07.007&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c90338acb376476f948b9e2e9c334510
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-5586&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-5586&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-5586&client=summon